Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Leerink Partnrs lifted their FY2024 earnings estimates for Kyverna Therapeutics in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($3.33) for the year, up from their prior estimate of ($3.54). The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics' Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($4.35) EPS, FY2026 earnings at ($4.73) EPS, FY2027 earnings at ($5.68) EPS and FY2028 earnings at ($6.03) EPS.
Other research analysts have also issued reports about the stock. HC Wainwright reiterated a "neutral" rating and set a $7.00 price target on shares of Kyverna Therapeutics in a research note on Thursday, September 19th. Wells Fargo & Company cut their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday. JPMorgan Chase & Co. reduced their price objective on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. UBS Group assumed coverage on shares of Kyverna Therapeutics in a report on Thursday, October 10th. They issued a "buy" rating and a $13.00 target price for the company. Finally, Rodman & Renshaw started coverage on shares of Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a "buy" rating and a $16.00 price target for the company. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $25.86.
Check Out Our Latest Stock Report on KYTX
Kyverna Therapeutics Stock Performance
KYTX stock traded up $0.06 during trading on Monday, hitting $4.41. The company had a trading volume of 258,384 shares, compared to its average volume of 456,952. The firm has a 50-day moving average price of $5.46 and a 200-day moving average price of $8.42. Kyverna Therapeutics has a 1-year low of $4.30 and a 1-year high of $35.06.
Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million during the quarter.
Institutional Trading of Kyverna Therapeutics
A number of large investors have recently made changes to their positions in KYTX. Price T Rowe Associates Inc. MD acquired a new stake in shares of Kyverna Therapeutics during the 1st quarter worth about $23,093,000. Novo Holdings A S grew its stake in Kyverna Therapeutics by 150.0% in the 2nd quarter. Novo Holdings A S now owns 1,750,000 shares of the company's stock worth $13,125,000 after acquiring an additional 1,050,000 shares during the period. E Fund Management Co. Ltd. purchased a new stake in Kyverna Therapeutics in the 2nd quarter worth approximately $1,421,000. Great Point Partners LLC lifted its stake in shares of Kyverna Therapeutics by 232.8% during the 2nd quarter. Great Point Partners LLC now owns 499,152 shares of the company's stock worth $3,744,000 after purchasing an additional 349,152 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in shares of Kyverna Therapeutics in the first quarter valued at $15,041,000. Institutional investors and hedge funds own 18.08% of the company's stock.
About Kyverna Therapeutics
(
Get Free Report)
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Further Reading
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
